GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Propanc Biopharma PPCB · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.76

-0.56%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Propanc Biopharma

From its filings with the US Securities and Exchange Commission

SEC filings

Propanc Biopharma is based in Camberwell, Victoria, Australia and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PPCB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 June 2026, it reported a net loss of $18.9m. At that date it held total assets of $12.8m and shareholders' equity of $9.4m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
15 Jun 2012
Employees
1
Website
propanc.com ↗
Head office
302/6 BUTLER STREET, CAMBERWELL, VICTORIA, C3, 3124
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. James NathanielszChief Executive Officer, Treasurer, Director, since 2025$167,898
  • Ms. Jeannine ZimmermanChief Financial Officer
  • Dr. Ralf BrantDirector
  • Mr. Josef ZelingerDirector
  • Mr. Joseph HimyIndependent Director
  • Ms. Annie VanbroekhovenIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Develops cancer treatments focusing on tumor recurrence prevention
  • Has a unique pro-enzyme therapy for carcinomas from solid tumors
  • Operates with a single full-time employee as a development-stage company

Weaknesses

  • Limited employee count of one full-time employee
  • IPO occurred in 2012, indicating a long development stage
  • No mention of commercialized products or revenue streams

Opportunities

  • Potential for developing PRP and PRP-DCM into marketable therapies
  • Growing focus on cancer treatment solutions in healthcare sector
  • Opportunity to expand from development-stage to commercial operations

Threats

  • Development-stage status with no commercialized products
  • Dependence on unproven pro-enzyme therapy technology
  • Long time since IPO without significant commercial progress

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.